文献速递肾小球疾病

Narsoplimab(一种新型MASP-2抑制剂)治疗IgA肾病的安全性、耐受性和疗效

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2020-08-13

这项分期2期研究评估了抗MASP-2单抗narsoplimab在高危IgA肾病患者中的安全性和有效性。亚研究1为单臂开放标签,亚研究2为随机双盲对照。结果显示narsoplimab安全耐受,亚研究1中4例患者24小时尿蛋白较基线下降54%至95%,亚研究2中两组蛋白尿下降相似,扩展期8例患者中位下降61.4%,eGFR保持稳定。

要点

  • narsoplimab在高危IgA肾病患者中安全耐受,常见不良事件为头痛、上呼吸道感染和乏力。
  • 亚研究1中4例患者24小时尿蛋白较基线下降54%至95%。
  • 扩展期8例患者中位24小时尿蛋白下降61.4%,eGFR保持稳定。

核心结论

  • 中期分析提示narsoplimab治疗在高危晚期IgA肾病患者中安全、耐受良好,可能带来有临床意义的蛋白尿下降和eGFR稳定。

研究设计与样本

  • 分期2期研究,亚研究1为单臂开放标签研究,12例每周输注narsoplimab并逐渐减量糖皮质激素,随访6周。
  • 亚研究2将患者1:1随机分配接受每周narsoplimab或载体输注12周,随访6周后两组均可进入开放标签扩展期。

主要发现

  • 最常见不良事件包括头痛、上呼吸道感染和乏力,大多数为轻中度且短暂,未报告治疗相关严重不良事件。
  • 亚研究1中4例患者第18周24小时尿蛋白排泄较基线下降54%至95%。
  • 亚研究2中载体组和narsoplimab组第18周蛋白尿下降相似。
  • 8例患者(载体组3例,narsoplimab组5例)继续进入给药扩展期并均接受narsoplimab,基线后31至54周中位24小时尿蛋白排泄下降61.4%。
  • 两个亚研究中eGFR均保持稳定。

临床怎么用

  • 对于高危晚期IgA肾病患者,narsoplimab可能作为降低蛋白尿和保护肾功能的新选择,但需等待3期研究进一步验证。

局限性

  • 本研究为中期分析,样本量小,亚研究1为单臂设计,亚研究2随机阶段样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Narsoplimab is a human monoclonal antibody against mannan-associated lectin-binding serine protease-2 (MASP-2). Now in a phase 3 study, narsoplimab was evaluated in a staged phase 2 study assessing safety and effectiveness in high-risk patients with IgA nephropathy (IgAN). METHODS: Substudy 1 was a single-arm open-label study of 12 weekly infusions and tapered corticosteroids, with 6 weeks of follow-up. In substudy 2, patients were randomized 1:1 to receive a course of treatment consisting of once-weekly narsoplimab or vehicle infusions for 12 weeks. After 6 weeks of follow-up, both substudy 2 groups could continue in an open-label extension, receiving 1 or more narsoplimab courses at the investigator's discretion. RESULTS: The most commonly reported adverse events (AEs) included headache, upper respiratory infection, and fatigue. Most AEs were mild or moderate and transient. No treatment-related serious AEs were reported. All 4 patients who were enrolled in substudy 1 had reductions in 24-hour urine protein excretion (UPE) at week 18, ranging from 54% to 95% compared with baseline. In substudy 2, the vehicle and narsoplimab groups had similar proteinuria reductions at week 18. Eight patients (3 vehicle, 5 narsoplimab) continued in the dosing extension; all received narsoplimab. Median reduction in 24-hour UPE in these 8 patients was 61.4% at 31 to 54 weeks postbaseline. Estimated glomerular filtration rates (eGFR) remained stable in both substudies. CONCLUSION: This interim analysis suggests that narsoplimab treatment is safe, is well tolerated, and may result in clinically meaningful reductions in proteinuria and stability of eGFR in high-risk patients with advanced IgAN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lafayette RA, Rovin BH, Reich HN, et al. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney Int Rep. 2020. PMID: 33163724. doi:10.1016/j.ekir.2020.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。